These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 15621843)

  • 1. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma.
    Visani G; Guiducci B; D'Adamo F; Mele A; Nicolini G; Leopardi G; Sparaventi G; Barulli S; Malerba L; Isidori A; Malagola M; Piccaluga PP
    Leuk Lymphoma; 2005 Mar; 46(3):477-9. PubMed ID: 15621843
    [No Abstract]   [Full Text] [Related]  

  • 2. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
    Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
    Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients].
    Moreno M; Sancho JM; Gardella S; Coll R; García O; Gallardo D; Ribera JM
    Med Clin (Barc); 2010 Jan; 134(2):72-5. PubMed ID: 19913261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma.
    Ennishi D; Yokoyama M; Mishima Y; Watanabe C; Terui Y; Takahashi S; Takeuchi K; Ikeda K; Tanimoto M; Hatake K
    Leuk Lymphoma; 2007 Nov; 48(11):2241-3. PubMed ID: 17990181
    [No Abstract]   [Full Text] [Related]  

  • 5. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab.
    Zell JA; Yoon EJ; Ignatius Ou SH; Hoefs JC; Chang JC
    Anticancer Drugs; 2005 Jan; 16(1):83-5. PubMed ID: 15613909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.
    Lim KH; Yoon HI; Kang YA; Lee KW; Kim JH; Bang SM; Lee JH; Lee CT; Lee JS
    Korean J Intern Med; 2010 Mar; 25(1):86-92. PubMed ID: 20195409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Skin lesions in a female patient with non-Hodgkin lymphoma].
    Ducasse VO; Pintado JA; Gordon MM; Oyonarte MC
    Enferm Infecc Microbiol Clin; 2007; 25(7):489-90. PubMed ID: 17692217
    [No Abstract]   [Full Text] [Related]  

  • 8. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma.
    Venhuizen AC; Hustinx WN; van Houte AJ; Veth G; van der Griend R
    Eur J Haematol; 2008 Mar; 80(3):275-6. PubMed ID: 18005387
    [No Abstract]   [Full Text] [Related]  

  • 9. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma.
    Kilickap S; Yavuz B; Aksoy S; Sahiner L; Dincer M; Harputluoglu H; Erman M; Aytemir K; Tokgozoglu L; Barista I
    Med Oncol; 2008; 25(4):437-42. PubMed ID: 18415035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study Group.
    Sonneveld P; Hop W; Mulder AH; Michiels JJ; Blijham G; van de Lelie J; Raemakers JW; Nieuwenhuis K; van der Heul C
    Semin Hematol; 1994 Apr; 31(2 Suppl 3):9-12. PubMed ID: 8073309
    [No Abstract]   [Full Text] [Related]  

  • 11. Sarcoid-like reaction in the spleen following chemotherapy for non-Hodgkin's lymphoma.
    Reilly TB; Schuster DM; Starsiak MD; Kost CB; Halkar RK
    Clin Nucl Med; 2007 Jul; 32(7):569-71. PubMed ID: 17581351
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of elderly patients with non-Hodgkin's lymphoma].
    Titorenko IB; Kriachok IA
    Lik Sprava; 2011; (5-6):79-85. PubMed ID: 22606896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.
    Derenzini E; Stefoni V; Pellegrini C; Fina MP; Broccoli A; Venturini F; Gandolfi L; Pileri SA; Martelli M; Petti MC; Perrotti A; De Renzo A; Zaja F; Baccarani M; Zinzani PL
    Leuk Lymphoma; 2009 Nov; 50(11):1824-9. PubMed ID: 19814687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Supportive care for patients with non-Hodgkin lymphoma receiving R-CHOP chemotherapy].
    Kato H
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():636-41. PubMed ID: 25831838
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.
    Coiffier B
    Tumori; 2002; 88(1 Suppl 1):S26-8. PubMed ID: 11989916
    [No Abstract]   [Full Text] [Related]  

  • 16. Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.
    Case DC; Desch CE; Kalman LA; Vongkovit P; Mena RR; Fridman M; Allen B
    Clin Lymphoma Myeloma; 2007 Mar; 7(5):354-60. PubMed ID: 17562245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens. The Nebraska Lymphoma Study Group.
    Vose JM; Anderson JR; Bierman PJ; Bast M; Weisenburger D; Chan WC; Bishop MR; Armitage JO
    Semin Hematol; 1994 Apr; 31(2 Suppl 3):4-8. PubMed ID: 7521065
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemoradiotherapy for localized non-Hodgkin's lymphoma.
    Cosset JM
    N Engl J Med; 1998 Jul; 339(1):44-5. PubMed ID: 9647881
    [No Abstract]   [Full Text] [Related]  

  • 19. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.
    Sparano JA; Lee JY; Kaplan LD; Levine AM; Ramos JC; Ambinder RF; Wachsman W; Aboulafia D; Noy A; Henry DH; Von Roenn J; Dezube BJ; Remick SC; Shah MH; Leichman L; Ratner L; Cesarman E; Chadburn A; Mitsuyasu R;
    Blood; 2010 Apr; 115(15):3008-16. PubMed ID: 20023215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Flinn IW; Spigel DR; Clark BL; Griner PL; Vazquez ER; Doss HH; Shipley D; Franco LA; Burris HA; Greco FA;
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):44-50. PubMed ID: 20223728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.